In the current therapeutic landscape of CLL, which ranges from CIT to mAb and target therapy, the molecular status of IGHV and TP53 genes provides robust predictors for treatment decision making and must be routinely assessed in the clinical practice in cases requiring treatment [13]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.